Javier Munoz, MD, MS, FACP, of the Mayo Clinic, considers the appropriateness for CAR T-cell therapy for a 66-year-old woman with relapsed/refractory mantle cell lymphoma.
Case: A 66-Year-Old Woman With Mantle Cell Lymphoma
History
A 66-year-old woman diagnosed with mantle cell lymphoma in 2017
She was treated with rituximab, dexamethasone, cytarabine + carboplatin followed by autologous stem cell rescue; achieved PR;
Continued on rituximab maintenance therapy
In 2019 she experienced clinical relapse and was started on acalabrutinib; achieved SD
Currently
She complains of a 3-month history of intermittent fatigue, nausea and dyspnea on exertion